KMDA KAMADA LTD IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1567529 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY12.1%
TTM net income YoY39.7%
TTM EPS YoY40.0%
Revenue 3-yr CAGR-0.1%
Net income 3-yr CAGR—
Margins
Gross margin42.3%
Operating margin14.5%
Net margin11.2%
FCF margin—
EBITDA margin15.4%
Returns
ROE7.6%
ROA5.4%
ROIC (approx.)12.1%
Asset turnover0.48x
Leverage & solvency
Liabilities / assets29.0%
Debt / equity0.00x
Current ratio4.07x
Interest coverage30.36x
Cash quality & payout
Operating cash flow / net income1.26x
Accruals ratio-1.4%
Payout ratio114.2%
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $180.46M | $160.95M |
| Cost of revenue | $104.05M | $90.99M |
| Gross profit | $76.41M | $69.97M |
| R&D expense | $12.99M | $15.19M |
| SG&A expense | $18.72M | $15.70M |
| Operating income | $26.23M | $20.05M |
| Interest expense | $864,000 | $660,000 |
| Pretax income | $23.47M | $13.33M |
| Income tax | $3.27M | -$1.13M |
| Net income | $20.20M | $14.46M |
| EBITDA | $27.87M | $21.54M |
| EPS (basic) | 0.35 | 0.25 |
| EPS (diluted) | 0.35 | 0.25 |
| Weighted avg. shares (diluted) | 58.35M | 57.82M |
| Balance sheet | ||
| Cash & equivalents | $75.47M | $78.44M |
| Receivables | $27.01M | $21.55M |
| Inventory | $84.94M | $78.82M |
| Current assets | $193.07M | $184.35M |
| PP&E, netmay include right-of-use assets (IFRS) | $41.37M | $36.24M |
| Goodwill | $30.31M | $30.31M |
| Total assets | $378.71M | $372.25M |
| Current liabilities | $47.39M | $49.39M |
| Short-term debt | $9.92M | $10.18M |
| Total liabilities | $109.64M | $112.79M |
| Shareholders' equity | $269.07M | $259.46M |
| Shares outstanding | 57.69M | 57.51M |
| Cash flow statement | ||
| Operating cash flow | $25.49M | $47.59M |
| Investing cash flow | -$9.84M | -$10.74M |
| Financing cash flow | -$18.34M | -$13.91M |
| Depreciation & amortization | $1.64M | $1.49M |
| Stock-based compensation | $845,000 | $874,000 |
| Dividends paid | $11.53M | — |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.